Precision Cancer Medicines & Immunotherapy for Lung Cancer
Treatment & Management of Non Small Cell Lung Cancer
Newsletter Signup | Join Community | Cancer Types
Imfinzi immunotherapy significantly improves treatment of stage III NSCLC - 50% of patients survive 4 years .
Gavreto now FDA approved for the treatment of RET positive NSCLC
c-Met inhibitor Capmatinib precision cancer medicine for the treatment of NSCLC targeting Met exon 14 FDA approved.
Retevmo is a precision cancer medicine that targets RET in some NSCLC patients.
Dual immunotherapy with Tiragolumab + Tecentriq improves survival among NSCLC patients.
Lobrena - a third generation ALK inhibitor drug with excellent CNS activity
Chemotherapy, biomarker testing and precision cancer medicines and immunotherapy are used to treat stage IIIB-IV NSCLC.
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…